Lv1
38 积分 2022-01-27 加入
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
12小时前
已完结
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
1天前
已完结
Advanced, recurrent, and persistent cervical cancer management: in the era of immunotherapy
9天前
已完结
皖公网安备34019202002308
